Myriad Genetics Q3 revenue $205.7M (-4% YoY); adjusted EPS $0.00; reaffirms FY2025 guidance

MYRIAD GENETICS INC

2025-Q3 EPS reported -$3.88 revenue$614,700,000

Q3 revenue $205.7M, down 4% YoY; flat excluding $8.1M headwinds (UNH GeneSight loss, EndoPredict divestiture).
GAAP net loss $27.4M ($0.29 loss); adjusted EPS $0.00; adjusted EBITDA $10.3M.
Hereditary cancer testing volume +11% YoY; GeneSight revenue -19% YoY due to UnitedHealthcare coverage change.
Entered strategic CDx collaboration with SOPHiA GENETICS for liquid biopsy companion diagnostics.
Reiterates FY2025 revenue $818-828M, gross margin 69.5-70%, adjusted EBITDA $27-33M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.